The Risk Factors for Cervical Cytological Abnormalities Among Women Infected With Non-16/18 High-Risk Human Papillomavirus: Cross-sectional Study
- PMID: 36480259
- PMCID: PMC9782330
- DOI: 10.2196/38628
The Risk Factors for Cervical Cytological Abnormalities Among Women Infected With Non-16/18 High-Risk Human Papillomavirus: Cross-sectional Study
Abstract
Background: High-risk human papillomavirus (hrHPV) infection is a necessary cause of almost all cervical cancers. Relative to hrHPV 16/18 infection, non-16/18 hrHPV infection is of less concern. However, the increasing prevalence of non-16/18 hrHPV infections has become an important public health issue. The early identification and treatment of cervical cytological abnormalities in women infected with non-16/18 hrHPV reduces the incidence of cervical cancer. To date, no study has examined the risk factors for cytological abnormalities in this high-risk population.
Objective: This population-based, cross-sectional study aimed to identify the risk factors for cervical cytological abnormalities in women infected with non-16/18 hrHPV.
Methods: A total of 314,587 women from the general population were recruited for cervical cancer screening at 136 primary care hospitals in Xiangyang, China. Of these, 311,604 women underwent HPV genotyping, and 17,523 non-16/18 hrHPV-positive women were referred for cytological screening according to the screening program. A logistic regression model was used to assess the risk factors for cytological abnormalities among these non-16/18 hrHPV-positive women. A separate analysis was performed to determine the factors influencing high-grade cytological abnormalities.
Results: The non-16/18 hrHPV infection rate was 5.88% (18,323/311,604), which was 3-fold higher than that of hrHPV 16/18 (6068/311,604, 1.95%). Among the non-16/18 hrHPV-positive women who underwent ThinPrep cytologic test, the overall prevalence rates of cervical cytological abnormalities and high-grade cytological abnormalities were 13.46% (2359/17,523) and 1.18% (206/17,523), respectively. Multivariate logistic regression analysis revealed that women with middle or high school educational attainment were at a higher risk of having cytological abnormalities than those who received primary education (odds ratio [OR] 1.31, 95% CI 1.17-1.45; P<.001, and OR 1.32, 95% CI 1.14-1.53; P<.001, respectively). Living in rural areas (OR 2.58, 95% CI 2.29-2.90; P<.001), gravidity ≥3 (OR 2.77, 95% CI 1.19-6.45; P=.02), cervix abnormalities detected in pelvic examination (OR 1.22, 95% CI 1.11-1.34; P<.001), and having a cervical cancer screening 3 years ago (OR 0.79, 95% CI 0.62-1.00; P=.048) were associated with cytological abnormalities. The risk factors for high-grade cytological abnormalities included middle school education (OR 1.45, 95% CI 1.07-1.98; P=.02), living in rural regions (OR 1.52, 95% CI 1.10-2.10; P=.01), and cervix abnormality (OR 1.72, 95% CI 1.30-2.26; P<.001).
Conclusions: The dominant epidemic of non-16/18 hrHPV infection is revealed in Chinese women. Multiple risk factors for cervical cytological abnormalities have been identified in women infected with non-16/18 hrHPV. These findings can provide important information for clinically actionable decisions for the screening, early diagnosis, intervention, and prevention of cervical cancer in non-16/18 hrHPV-positive women.
Keywords: cervical cancer; cervical cytological abnormalities; education; gravidity; logistic regression; non-16/18 high-risk human papillomavirus; pelvic examination; risk factors; rural; screening.
©Ting Xiao, Chun-Quan Ou, Jun Yang, Chunhua Wang, Mei Yang, Tingyu Yu, Liang Shen, Xiaohan Xu, Hui Xing. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 08.12.2022.
Conflict of interest statement
Conflicts of Interest: None declared.
Figures


Similar articles
-
Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark - the SHADE.BMC Cancer. 2016 Nov 8;16(1):866. doi: 10.1186/s12885-016-2881-1. BMC Cancer. 2016. PMID: 27821088 Free PMC article.
-
Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.JAMA Oncol. 2021 Feb 1;7(2):263-270. doi: 10.1001/jamaoncol.2020.6575. JAMA Oncol. 2021. PMID: 33377903 Free PMC article. Clinical Trial.
-
Changes in High-Risk HPV Infection Prevalence and Associated Factors in Selected Rural Areas of China: A Multicenter Population-Based Study.Front Med (Lausanne). 2022 Jul 12;9:911367. doi: 10.3389/fmed.2022.911367. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35903319 Free PMC article.
-
Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.Lancet Oncol. 2022 Jul;23(7):950-960. doi: 10.1016/S1470-2045(22)00294-7. Epub 2022 Jun 13. Lancet Oncol. 2022. PMID: 35709810
-
High-risk human papillomavirus infection among Nigerian women: A systematic review and meta-analysis.J Int Med Res. 2023 Jul;51(7):3000605231182884. doi: 10.1177/03000605231182884. J Int Med Res. 2023. PMID: 37409466 Free PMC article.
Cited by
-
Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.Cancer Med. 2024 Jun;13(11):e7316. doi: 10.1002/cam4.7316. Cancer Med. 2024. PMID: 38828559 Free PMC article.
-
Development of a clinical prediction model for pathological upgrading in low-grade squamous intraepithelial lesions following cervical conization.Cytojournal. 2024 Oct 11;21:37. doi: 10.25259/Cytojournal_7_2024. eCollection 2024. Cytojournal. 2024. PMID: 39563666 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660. - DOI - DOI - PubMed
-
- Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond) 2021 Oct;41(10):1037–1048. doi: 10.1002/cac2.12197. https://europepmc.org/abstract/MED/34288593 - DOI - PMC - PubMed
-
- Cao W, Chen H, Yu Y, Li N, Chen W. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021 Mar 17;134(7):783–791. doi: 10.1097/CM9.0000000000001474. https://europepmc.org/abstract/MED/33734139 00029330-202104050-00005 - DOI - PMC - PubMed
-
- Wu P, Xiong H, Yang M, Li L, Wu P, Lazare C, Cao C, Gao P, Meng Y, Zhi W, Lin S, Hu J, Wei J, Ma D, Liu J, Yin P, Xing H. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: a large population-based study. Gynecol Oncol. 2019 Dec;155(3):436–443. doi: 10.1016/j.ygyno.2019.10.003.S0090-8258(19)31560-4 - DOI - PubMed
-
- Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12–9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F - DOI - PubMed